Breakthrough in HIV Prevention: Lenacapavir Demonstrates 100% Efficacy for HIV Prevention

Researchers at the 25th International AIDS Conference in Munich, Germany, announced a significant breakthrough in HIV prevention using the novel twice-yearly injectable lenacapavir. The emerging data from the PURPOSE 1 trial demonstrated 100% efficacy in preventing HIV infection in cisgender women. The President of the International AIDS Society, Sharon Lewin, described the results as a 'breakthrough advance with huge public health potential.' However, concerns about pricing and access to the treatment remain, with advocates arguing that Gilead, the manufacturer, needs to allow generic lenacapavir prices under US$100 per person per year to make it accessible for mass treatment programs.

Key Takeaways:

• The PURPOSE 1 trial demonstrated 100% efficacy in preventing HIV infection in cisgender women using lenacapavir, a twice-yearly injectable.
• Gilead, the manufacturer, has been criticized for its pricing strategy, which could limit access to the treatment, especially for resource-limited countries.
• Researchers argue that Gilead needs to allow generic lenacapavir prices under US$100 per person per year to make it accessible for mass treatment programs.
• A pricing analysis suggests that lenacapavir can be mass-produced for US$63 to US$93 per person each year, which could fall to US$26 to US$40 per person if mass production is pursued.
• The researchers noted that these prices require voluntary licenses and competition between generic suppliers.
• Joyce Ouma, a senior programs officer at the Global Network of Young People Living with HIV, emphasized the need for fair access to lenacapavir in the Global South to meet the 2030 goal of ending new HIV transmissions.
• Gilead's spokesperson stated that the company awaits additional Phase 3 clinical trial data and regulatory filings before quoting a price for lenacapavir.

Statistics:

• The PURPOSE 1 trial involved over 3,000 participants from South Africa and Uganda.
• 1.3 million people were infected with HIV globally in 2023, translating to 2.4% or one infection in every 42 people, according to the Choice Agenda.
• Researchers estimate that lenacapavir can be mass-produced for US$63 to US$93 per person each year, which could fall to US$26 to US$40 per person if mass production is pursued.
• The researchers noted that if Gilead allows mass production of generic lenacapavir for under US$100 a year, millions of people at high risk of HIV could take lenacapavir and not be infected.

Sources:

• The International AIDS Society
• The Choice Agenda
• Gilead
• Andrew Hill, senior visiting research fellow in the Department of Pharmacology and Therapeutics at the University of Liverpool
• Joyce Ouma, senior programs officer at the Global Network of Young People Living with HIV